Charge Detection Mass Spectrometry: What's the "Big" Deal?

ABSTRACT

In 2002, the first fully humanized mAb was approved by the U.S. Food and Drug Administration (FDA) (3). [...]the biopharmaceutical industry is still in its infancy and new, more complex products are in development and will ikely dominant the market in the future. [...]the most common forms of LC-MS have limitations when characterizing large macromolecules (4). [...]in this column, we discuss the potential for charge detection MS (CDMS) as an analytical tool for characterizing large, complex, and heterogenous biopharmaceuticals. [...]in October 2021 at the American Association for Mass Spectrometry (ASMS) annua meeting in Philadelphia, TrueMass presented the first commercial CDMS (6,7). The cylinder is often inside an electrostatic linear ion trap (ELIT) instrument, where ions oscillate back and forth. [...]the oscillation frequency gives the m/z and the charge is determined by the magnitude.